Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Karolinska Invests In Swedish Firms

by Rick Mullin
January 25, 2010 | A version of this story appeared in Volume 88, Issue 4

Karolinska Development and BioChromix, a specialist in diagnosis and monitoring of Alzheimer’s disease, have formed a company to develop novel treatments for neurogenerative disorders by leveraging BioChromix’ expertise in luminescent conjugated polymers. Karolinska will own 28% of the new company. Stockholm-based Karolinska, which specializes in commercializing academic research, has also linked up with Uminova, a private equity firm dedicated to ventures associated with Sweden’s Umeå University and other regional institutions. The two firms will study investments in start-up life sciences companies.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.